内生场腹腔热灌注化疗治疗晚期原发性肝癌的临床观察

关铁; 邹庆华

内生场腹腔热灌注化疗治疗晚期原发性肝癌的临床观察

关铁,
邹庆华

中国石油天然气集团公司中心医院普外科

详细信息

中图分类号: R735.7
计量
- 文章访问数: 4075
- HTML全文浏览量: 19
- PDF下载量: 782
- 被引次数: 0
出版历程
- 出版日期: 2011-05-20

The clinical observation of continuous hyperthermic peritoneal perfusion chemotherapy with endogenetic field tumor hyperthemic system in the treatment of advanced primary hepatic carcinoma

摘要

摘要: 目的观察内生场腹腔热灌注化疗治疗晚期原发性肝癌患者的安全性和疗效。方法对42例晚期原发性肝癌患者进行以顺铂联合氟尿嘧啶为主的内生场腹腔热灌注化疗,观察化疗前后的效果。另39例原发性肝癌给予一般支持治疗。结果经腹腔热灌注化疗,总有效率(RR)59.5%,腹水控制率81%,两组差异有统计学意义。治疗组和对照组中位生存期分别为17个月和3个月,差异有统计学意义(P<0.05)。治疗组和对照组累计生存率比较差异有统计学意义(P<0.05)。副作用主要为乏力、出汗。结论内生场腹腔热灌注化疗对晚期原发性肝癌有较好的控制,且安全性好。
- 化学疗法,肿瘤,局部灌注 /
- 高温,诱发 /
- 肝肿瘤 /
- 腹腔热灌注化疗
Abstract: Objective To observe the effects and adverse reactions of continuous hyperthermic peritoneal perfusion chemotherapy with endogenetic field tumor hyperthemic system in the treatment of 81 patients with primary hepatic carcinoma.Methods 42 patients with primary hepatic carcinoma were treated with DDP and 5-FU by CHPPC and 39 patients were treated with support therapy.Results The overall response rate of the CHPPC was 59.5% and the complete remission rate of ascites was 81%.There was a significant difference between the two groups (P<0.05) .The median survival time of the treatment group and the control group were 17 months and 3 months respectively;there was a significant difference between the two groups (P<0.05) .The cumulative survival rate was significantly different between the treatment group and the control group (P<0.05) .The main side effects were fatigue and sweatiness.Conclusion CHPPC with endogenetic field tumor hyperthemic system for advanced primary hepatic carcinoma is safe and feasible.
- chemotherapy /
- cancer /
- regional perfusion /
- hyperthermia

HTML全文

参考文献(8)

[1]Fujimoto S, Shrestha RD, Kokubun M, et al.Intraperitoneal hyperthermic perfusion combined with surgery effective for gastric cancer patients with peritoneal seeding[J].Ann Surg, 1988, 208 (1) :36-41.

[2]陈文华, 任林广, 宋连生.腹腔热灌注化疗透热治疗恶性肿瘤148例分析[J].中国误诊学杂志, 2008, 11 (8) :2736.

[3]陈青娟, 李曾, 王东风, 等.热灌注化疗治疗恶性腹盆腔肿瘤的临床观察现代肿瘤医学[J].2008, 12 (16) :2161-2163.

[4]Hildebrandt B, Wust P, Ahlers O, et al.The cellular and molecular basis of hyperthemia[J].Crit Rev Oncol Hematol, 2002, 43 (1) :33-56.

[5]Wiedemann GJ, Robins HI, Katschinski DM, et al.Systemic hyperthemia and ICE chemotherapy for sarcoma patients;rationale and clinical status[J].Anticancer Res, 1997, 17 (4B) :2899-2902.

[6]Sticca RP, Dach BW.Rationale for hyperthermia with intraoperative intraperitoneal chemotherapy agent[J].Surg Oncol Clin N Am, 2003, 12 (3) :689-701.

[7]魏志刚, 卿三华.腹腔热灌注化疗治疗胃肠癌[J].世界华人消化杂志, 2006, 14 (2) :134-137.

[8]张积仁, 刘端祺.肿瘤物理治疗新技术[M].北京:人民军医出版社, 2005:10.

施引文献

资源附件(0)

访问统计